Management of Chemotherapy Side Effects — MCQs
Which of the following is the primary neurotransmitter involved in nausea and vomiting associated with chemotherapy?
Which of the following drugs is not associated with significant cardiotoxicity?
Many drugs are used as rescue therapy for preventing the adverse effects of anticancer drugs. Folinic acid is used in:-
A patient with a malignancy is undergoing chemotherapy. The platelet counts were reduced after the previous cycle of chemotherapy. Which of the following drugs can be used to treat this patient?
A 50-year-old woman is discovered to have metastatic breast cancer and develops bacterial pneumonia one week after receiving her first dose of chemotherapy. Which of the following best explains this patient's susceptibility to bacterial infection?
A 7 – year old boy presented with abdominal pain, vomiting, oliguria, and periorbital puffiness following chemotherapy. Investigations reveal hyperuricemia, raised creatinine levels, and hyperkalemia. What is the next best step in the management of this condition ?
A 55-year-old woman is undergoing chemotherapy for breast cancer and experiences severe nausea and vomiting. Which antiemetic, recognized for its minimal extrapyramidal side effects, would be appropriate for her condition?
Which Benzodiazepine decreases post-operative nausea & vomiting:-
Hand foot syndrome is an adverse effect of what?
A G2 P1 - 29-year-old female delivered a baby, but the baby died within 48 hours due to medical reasons. What drug will you advise to stop breast milk secretion?
Management of Chemotherapy Side Effects Indian Medical PG Practice Questions and MCQs
Question 1: Which of the following is the primary neurotransmitter involved in nausea and vomiting associated with chemotherapy?
- A. Dopamine
- B. Acetylcholine
- C. GABA
- D. Serotonin (Correct Answer)
Explanation: ***Serotonin*** - **Serotonin (5-HT)**, particularly acting on **5-HT3 receptors**, is a major neurotransmitter mediating chemotherapy-induced nausea and vomiting (CINV). - Chemotherapeutic agents can damage **enterochromaffin cells** in the gastrointestinal tract, leading to the release of serotonin, which then stimulates vagal afferents and the **chemoreceptor trigger zone (CTZ)**. *Dopamine* - **Dopamine (D2 receptors)** plays a role in nausea and vomiting, particularly in the **chemoreceptor trigger zone (CTZ)**. - While dopamine antagonists can be used as antiemetics, **serotonin** is considered the primary neurotransmitter in CINV due to the direct impact of chemotherapy on serotonin release. *Acetylcholine* - **Acetylcholine** is involved in motion sickness and is targeted by **anticholinergic antiemetics (e.g., scopolamine)**. - Its primary role in CINV is less significant compared to serotonin, which has a more direct link to the mechanisms of chemotherapy. *GABA* - **GABA (gamma-aminobutyric acid)** is the main inhibitory neurotransmitter in the brain and can reduce anxiety and modulate vomiting. - While **benzodiazepines**, which enhance GABAergic activity, are used as adjuncts in CINV to reduce **anticipatory nausea** and anxiety, GABA itself is not the primary mediator of the emetic response to chemotherapy.
Question 2: Which of the following drugs is not associated with significant cardiotoxicity?
- A. 5-Fluorouracil
- B. Cyclophosphamide
- C. Doxorubicin
- D. Cisplatin (Correct Answer)
Explanation: ***Cisplatin*** - While cisplatin is associated with various toxicities, including **nephrotoxicity** and **neurotoxicity**, significant **cardiotoxicity** (like cardiomyopathy or severe arrhythmias) is much less common compared to the other listed agents. - Its primary cardiac effects are often indirect, such as electrolyte disturbances, or less severe, making it the least cardiotoxic among the options. *5-Fluorouracil* - This drug is known to cause **coronary vasospasm**, leading to **angina** or **myocardial infarction** in some patients. - The cardiotoxicity can manifest as **ischemic events** and **arrhythmias**, particularly during or shortly after infusion. *Cyclophosphamide* - High doses of cyclophosphamide can induce **hemorrhagic myocarditis** and **congestive heart failure**, particularly in the setting of bone marrow transplantation. - It causes direct myocardial damage and can lead to rapid-onset cardiac dysfunction. *Doxorubicin* - Doxorubicin is a well-known cause of **dose-dependent cardiomyopathy**, which can lead to **irreversible heart failure**. - Its cardiotoxicity can be acute (arrhythmias, pericarditis-myocarditis syndrome) or chronic (dilated cardiomyopathy).
Question 3: Many drugs are used as rescue therapy for preventing the adverse effects of anticancer drugs. Folinic acid is used in:-
- A. Cyclophosphamide toxicity
- B. Doxorubicin toxicity
- C. Methotrexate toxicity (Correct Answer)
- D. Cisplatin toxicity
Explanation: ***Methotrexate toxicity*** - **Folinic acid (leucovorin)** is a reduced folate that bypasses the metabolic block caused by **methotrexate** on dihydrofolate reductase. - It replenishes the body's **folate stores** and protects healthy cells from methotrexate's cytotoxic effects, particularly in the bone marrow and gastrointestinal tract. *Cyclophosphamide toxicity* - **Cyclophosphamide** toxicity, primarily hemorrhagic cystitis, is prevented by **mesna** (2-mercaptoethane sulfonate). - Mesna inactivates the urotoxic metabolite **acrolein** in the urine, preventing bladder damage. *Doxorubicin toxicity* - **Doxorubicin** causes cardiotoxicity, which can be mitigated by the iron-chelating agent **dexrazoxane**. - Dexrazoxane reduces the formation of **free radicals** that contribute to doxorubicin-induced myocardial damage. *Cisplatin toxicity* - **Cisplatin** toxicity, especially nephrotoxicity, is largely prevented by **aggressive hydration** and administration of **diuretics**. - **Amifostine** is another agent that can reduce cisplatin-induced nephrotoxicity, neurotoxicity, and ototoxicity by acting as a cytoprotectant.
Question 4: A patient with a malignancy is undergoing chemotherapy. The platelet counts were reduced after the previous cycle of chemotherapy. Which of the following drugs can be used to treat this patient?
- A. Oprelvekin (IL-11) - stimulates platelet production (Correct Answer)
- B. Filgrastim - stimulates white blood cell production
- C. Amifostine - protects against chemotherapy toxicity
- D. Erythropoietin - stimulates red blood cell production
Explanation: ***Oprelvekin (IL-11) - stimulates platelet production*** - **Oprelvekin** is a recombinant interleukin-11 (IL-11) that directly stimulates the proliferation and maturation of **megakaryocytes**, leading to increased platelet production. - It is specifically indicated for the prevention of **severe thrombocytopenia** and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy. *Filgrastim - stimulates white blood cell production* - **Filgrastim** is a **granulocyte colony-stimulating factor (G-CSF)** that primarily acts on neutrophil precursors, promoting their proliferation and maturation. - It is used to prevent and treat **neutropenia** and reduce the incidence of febrile neutropenia, but it does not significantly affect platelet counts. *Amifostine - protects against chemotherapy toxicity* - **Amifostine** is a **cytoprotective agent** that reduces toxicities associated with chemotherapy and radiation by preferentially protecting non-malignant cells. - It does not directly stimulate blood cell production but rather acts as a **free radical scavenger** to mitigate damage from cytotoxic treatments. *Erythropoietin - stimulates red blood cell production* - **Erythropoietin** is a **hematopoietic growth factor** that specifically stimulates the production of **red blood cells** by promoting the proliferation and differentiation of erythroid progenitor cells. - It is used to treat **anemia**, particularly in patients with chronic kidney disease or those undergoing chemotherapy, but it has no role in managing thrombocytopenia.
Question 5: A 50-year-old woman is discovered to have metastatic breast cancer and develops bacterial pneumonia one week after receiving her first dose of chemotherapy. Which of the following best explains this patient's susceptibility to bacterial infection?
- A. Depletion of serum complement
- B. Impaired neutrophil respiratory burst
- C. Inhibition of clotting factor activation
- D. Neutropenia (Correct Answer)
Explanation: ***Neutropenia*** - **Chemotherapy** often causes **bone marrow suppression**, leading to a decrease in the absolute number of **neutrophils**, a condition known as neutropenia. - Neutrophils are crucial for the primary defense against **bacterial and fungal infections**, and their depletion significantly increases susceptibility, especially to **bacterial pneumonia**. *Depletion of serum complement* - While complement deficiency can increase susceptibility to certain infections, it is not a direct or common side effect of typical **chemotherapy regimens**. - Complement deficiencies are often **genetic** or related to specific **autoimmune diseases**, which are not indicated as the primary cause here. *Impaired neutrophil respiratory burst* - Impaired **neutrophil respiratory burst** (e.g., in **chronic granulomatous disease**) leads to a reduced ability to kill ingested bacteria, resulting in recurrent infections. - While chemotherapy can affect neutrophil function, severe impairment of the respiratory burst is not the primary mechanism of increased infection risk one week post-treatment; **neutropenia** is more immediate and profound. *Inhibition of clotting factor activation* - **Inhibition of clotting factor activation** would primarily manifest as **bleeding disorders**, not increased susceptibility to bacterial infections. - Chemotherapy can affect platelet count and function, but this mechanism does not directly explain increased risk of **bacterial pneumonia**.
Question 6: A 7 – year old boy presented with abdominal pain, vomiting, oliguria, and periorbital puffiness following chemotherapy. Investigations reveal hyperuricemia, raised creatinine levels, and hyperkalemia. What is the next best step in the management of this condition ?
- A. Hydration (Correct Answer)
- B. Probenecid
- C. Allopurinol
- D. Rasburicase
Explanation: ***Hydration*** - This patient presents with **tumor lysis syndrome (TLS)**, characterized by rapid tumor cell breakdown releasing intracellular contents (uric acid, potassium, phosphate) following chemotherapy. - **Aggressive intravenous hydration** is the **first-line and most critical initial step** in TLS management, aiming to maintain urine output at 2-3 mL/kg/hour to prevent uric acid crystal precipitation in renal tubules. - Even with oliguria present, optimizing intravascular volume and renal perfusion is essential before other interventions can be effective - without adequate hydration, rasburicase-generated allantoin cannot be excreted. - **Hydration forms the foundation** upon which all other TLS therapies depend, making it the priority "next best step." *Probenecid* - **Probenecid** is a uricosuric agent that increases renal uric acid excretion by blocking tubular reabsorption. - It is **contraindicated in tumor lysis syndrome** as it increases uric acid concentration in renal tubules, potentially worsening uric acid nephropathy and crystal formation. *Allopurinol* - **Allopurinol** is a xanthine oxidase inhibitor that prevents new uric acid formation by blocking purine metabolism. - While valuable for **prophylaxis** in high-risk patients before chemotherapy, it **does not reduce existing hyperuricemia** in established TLS. - Less effective than rasburicase for treating active, symptomatic hyperuricemia. *Rasburicase* - **Rasburicase** is a recombinant urate oxidase that rapidly converts uric acid to allantoin (5-10 times more soluble). - Highly effective for **treating established hyperuricemia** in TLS and often used in severe cases. - However, as the "next best step," **hydration must be established first** to ensure adequate renal perfusion and allow excretion of metabolites - rasburicase is typically administered **after or concurrent with** hydration initiation. - In clinical practice, both are often started together, but hydration is the foundational intervention.
Question 7: A 55-year-old woman is undergoing chemotherapy for breast cancer and experiences severe nausea and vomiting. Which antiemetic, recognized for its minimal extrapyramidal side effects, would be appropriate for her condition?
- A. Metoclopramide
- B. Ondansetron (Correct Answer)
- C. Promethazine
- D. Prochlorperazine
Explanation: ***Ondansetron*** - **Ondansetron** is a 5-HT3 receptor antagonist, highly effective against chemotherapy-induced nausea and vomiting (CINV) due to its action on serotonin receptors in the **chemoreceptor trigger zone** and **gastrointestinal tract**. - It is known for its favorable side effect profile, with **minimal to no extrapyramidal symptoms**, making it a preferred choice in patients where such effects are a concern. *Metoclopramide* - While effective against nausea and vomiting, **metoclopramide** (a D2 receptor antagonist) can cause **extrapyramidal symptoms** such as **dystonia** and **tardive dyskinesia**, especially with prolonged use or higher doses. - Its mechanism of action includes both prokinetic effects and central antiemetic action, but its side effect profile makes it less ideal when avoiding extrapyramidal symptoms is a priority. *Promethazine* - **Promethazine** is a first-generation antihistamine with antiemetic properties, but it can cause significant **sedation** and has some **anticholinergic side effects**. - Although its extrapyramidal risk is lower than some other drugs, it's not the primary choice for chemotherapy-induced nausea due to its sedative effects and generally less potent antiemetic action for CINV compared to 5-HT3 antagonists. *Prochlorperazine* - **Prochlorperazine** is a phenothiazine antipsychotic with strong antiemetic effects, acting primarily as a **dopamine receptor antagonist**. - It carries a significant risk of **extrapyramidal side effects**, including **acute dystonia** and **parkinsonism**, making it less suitable when such side effects must be strictly avoided.
Question 8: Which Benzodiazepine decreases post-operative nausea & vomiting:-
- A. Midazolam (Correct Answer)
- B. Diazepam
- C. Lorazepam
- D. All of the options
Explanation: ***Midazolam*** - **Midazolam** is a commonly used benzodiazepine in anesthesia that has been shown to have **antiemetic properties** and can decrease the incidence of **postoperative nausea and vomiting (PONV)**. - Its mechanism may involve its sedative and anxiolytic effects, indirectly reducing the triggers for nausea. *Diazepam* - While **diazepam** is a benzodiazepine with sedative and anxiolytic effects, it is not primarily known for reducing PONV. - Its longer duration of action compared to midazolam can also contribute to unwanted **postoperative sedation**. *Lorazepam* - **Lorazepam** is another benzodiazepine used for anxiolysis and sedation but is not a primary agent for the prevention of PONV. - Like diazepam, its prolonged effects can lead to **delayed recovery** and drowsiness, which may not be desirable in the postoperative period. *All of the options* - While all listed drugs are benzodiazepines, only **midazolam** is consistently recognized and utilized for its ability to reduce PONV in the perioperative setting. - The other benzodiazepines do not demonstrate the same consistent benefit in PONV reduction and may have other side effects that limit their utility for this specific purpose.
Question 9: Hand foot syndrome is an adverse effect of what?
- A. Bleomycin
- B. Etoposide
- C. Actinomycin D
- D. 5-Fluorouracil (Correct Answer)
Explanation: ***5-Fluorouracil*** - **Hand-foot syndrome** (**palmar-plantar erythrodysesthesia**) is a common and dose-limiting side effect of 5-Fluorouracil and its prodrug, capecitabine. - It presents with **redness**, **swelling**, **pain**, and **desquamation** of the palms and soles. *Bleomycin* - The primary dose-limiting toxicity of bleomycin is **pulmonary fibrosis**, not hand-foot syndrome. - Other common toxicities include **hyperpigmentation** of the skin and mucocutaneous reactions, but not typically severe palmar-plantar changes. *Etoposide* - Etoposide is associated with adverse effects like **myelosuppression** (leukopenia, thrombocytopenia) and **alopecia**. - While skin reactions can occur, **hand-foot syndrome** is not a characteristic or common side effect of etoposide. *Actinomycin D* - Actinomycin D (dactinomycin) is known for causing **myelosuppression**, **nausea**, **vomiting**, and **mucositis**. - It can also cause **radiation recall phenomenon**, but not typically hand-foot syndrome as a primary or common adverse effect.
Question 10: A G2 P1 - 29-year-old female delivered a baby, but the baby died within 48 hours due to medical reasons. What drug will you advise to stop breast milk secretion?
- A. None of the options
- B. Ergot alkaloids
- C. Cabergoline (Correct Answer)
- D. Both B & C
Explanation: ***Cabergoline*** - **Cabergoline** is a **non-ergot dopamine agonist** that effectively inhibits pituitary prolactin secretion, leading to the suppression of lactation. - It works by acting on **D2 dopamine receptors** in the pituitary gland, thereby preventing milk secretion after delivery. - It is the **preferred first-line agent** for lactation suppression due to its superior efficacy, better tolerability, longer half-life (allowing single or twice-daily dosing over 2 days), and lower side effect profile. *None of the options* - This option is incorrect because there are specific pharmacological agents available and recommended for **lactation suppression** in such circumstances. - **Cabergoline** is a well-established and commonly used drug for this purpose. *Ergot alkaloids* - While **bromocriptine** (an ergot-derived dopamine agonist) was historically used for lactation suppression, it is no longer preferred. - **Cabergoline** has largely replaced bromocriptine due to better tolerability, longer half-life, less frequent dosing, and fewer side effects (bromocriptine causes more nausea, vomiting, and orthostatic hypotension). - Note: **Cabergoline itself is a non-ergot dopamine agonist**, making it pharmacologically distinct from ergot alkaloids. *Both B & C* - This option is incorrect because **cabergoline is not an ergot alkaloid**—it is a non-ergot dopamine agonist. - While bromocriptine (an ergot derivative) can suppress lactation, **cabergoline alone** is the preferred choice with superior efficacy and safety profile. - Combining or equating these agents is not standard clinical practice.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free